Ropes & Gray advised Adaptimmune Therapeutics on the transaction. Adaptimmune Therapeutics (NASDAQ: ADAP) announced it has entered into a clinical collaboration agreement with Galapagos NV (Euronext...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Adaptimmune Therapeutics plc on the transaction, and DLA Piper advised Hercules Capital. Adaptimmune Therapeutics plc (NASDAQ: ADAP), a clinical-stage biopharmaceutical company, announced...
You must be a Standard 1 Year member to access this content.
Goodwin advised TCR² Therapeutics Inc. on the deal while Ropes & Gray represented Adaptimmune Therapeutics plc. TCR² Therapeutics Inc. (NASDAQ: TCRR) announced its definitive agreement with Adaptimmune...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Adaptimmune in the deal. Adaptimmune signed its strategic collaboration with Roche Group’s Genentech Inc. to research, develop and commercialize cancer-target allogeneic T-cell...
You must be a Standard 1 Year member to access this content.
